Anita N. Haggstrom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anita N. Haggstrom has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Beth A. Drolet
Department of Dermatology University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA
7 shared publications- Ilona J. Frieden
Department of Dermatology University of California San Francisco California USA
7 shared publications Sarah L. Chamlin
Department of Pediatrics and Dermatology Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA
7 shared publicationsEulalia Baselga
Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain
5 shared publicationsJulie Powell
Division of Pediatric Dermatology Department of Pediatrics Sainte‐Justine University Hospital Centre University of Montreal Montreal QC Canada
5 shared publications- Anthony J. Mancini
Ann & Robert H. Lurie Children's Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
4 shared publications
Latest Publications
- 10 January 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 294-300
Severity of multisystem inflammatory syndrome in children (MIS‐C) in patients with and without mucocutaneous findings
Background: There are few studies comparing severity of MIS‐C disease with mucocutaneous symptoms, age, race, and ethnicity.Objective: To describe the mucocutaneous symptoms present on admission and evaluate whether these symptoms are correlated with a more severe MIS‐C disease course.Methods: Retrospective cohort study of hospitalized patients with suspected MIS‐C between May 13, 2020 to April 21, 2021.Results: Of the 66 patients who met the inclusion criteria, 84.8% (56/66) exhibited mucocutaneous findings. The most common mucocutaneous symptoms were rash, conjunctivitis, cracked lips, and sore throat. Children with mucocutaneous symptoms were younger (median 9.8 years) compared to those without (11.4 years), p = .39. The groups had similar proportions of pediatric intensive care unit admission, abnormal cardiology studies, and necessity of pressors. The presence of mucocutaneous findings on admission was associated with a lower troponin level on admission (median 0.08 ng/ml vs. 0.52, p = .003). Black children had higher odds of severe MIS‐C compared to White children (odds ratio [95% CI]: 3.30 [1.02, 10.72], p = .047). Children ≥5 years of age had greater odds of severe MIS‐C compared to children p = .02).Limitations: The sample size was relatively small, there was no dermatologist present on admission, initial diagnostic testing and management varied if patients presented at outside hospitals, and the CDC case definition for MIS‐C was highly sensitive.Conclusion: The presence of mucocutaneous symptoms negatively correlated with troponin levels, but there was no significant association between these symptoms and other markers of cardiac involvement (echocardiogram, ejection fraction, electrocardiogram).
- 10 January 2023
- Published by Wiley in Pediatric Dermatology
- Vol. 40 (2) , 294-300
Severity of multisystem inflammatory syndrome in children (MIS‐C) in patients with and without mucocutaneous findings
Background: There are few studies comparing severity of MIS‐C disease with mucocutaneous symptoms, age, race, and ethnicity.Objective: To describe the mucocutaneous symptoms present on admission and evaluate whether these symptoms are correlated with a more severe MIS‐C disease course.Methods: Retrospective cohort study of hospitalized patients with suspected MIS‐C between May 13, 2020 to April 21, 2021.Results: Of the 66 patients who met the inclusion criteria, 84.8% (56/66) exhibited mucocutaneous findings. The most common mucocutaneous symptoms were rash, conjunctivitis, cracked lips, and sore throat. Children with mucocutaneous symptoms were younger (median 9.8 years) compared to those without (11.4 years), p = .39. The groups had similar proportions of pediatric intensive care unit admission, abnormal cardiology studies, and necessity of pressors. The presence of mucocutaneous findings on admission was associated with a lower troponin level on admission (median 0.08 ng/ml vs. 0.52, p = .003). Black children had higher odds of severe MIS‐C compared to White children (odds ratio [95% CI]: 3.30 [1.02, 10.72], p = .047). Children ≥5 years of age had greater odds of severe MIS‐C compared to children p = .02).Limitations: The sample size was relatively small, there was no dermatologist present on admission, initial diagnostic testing and management varied if patients presented at outside hospitals, and the CDC case definition for MIS‐C was highly sensitive.Conclusion: The presence of mucocutaneous symptoms negatively correlated with troponin levels, but there was no significant association between these symptoms and other markers of cardiac involvement (echocardiogram, ejection fraction, electrocardiogram).
- 27 September 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 934-936
Development of an artificial intelligence algorithm for the diagnosis of infantile hemangiomas
Prompt and accurate diagnosis of infantile hemangiomas is essential to prevent potential complications. This can be difficult due to high rates of misdiagnosis and poor access to pediatric dermatologists. In this study, we trained an artificial intelligence algorithm to diagnose infantile hemangiomas based on clinical images. Our algorithm achieved a 91.7% overall accuracy in the diagnosis of facial infantile hemangiomas.
- 27 September 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (6) , 934-936
Development of an artificial intelligence algorithm for the diagnosis of infantile hemangiomas
Prompt and accurate diagnosis of infantile hemangiomas is essential to prevent potential complications. This can be difficult due to high rates of misdiagnosis and poor access to pediatric dermatologists. In this study, we trained an artificial intelligence algorithm to diagnose infantile hemangiomas based on clinical images. Our algorithm achieved a 91.7% overall accuracy in the diagnosis of facial infantile hemangiomas.
- Open Access
- 3 March 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 288-290
A rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis
A 4‐year‐old female with a history of atopic dermatitis developed herpes simplex virus (HSV) encephalitis while being treated with dupilumab and concomitant topical steroids. There was no prior history of HSV infections or immunodeficiency. To our knowledge, this is the first case of HSV encephalitis in a patient receiving dupilumab.
- 3 March 2022
- Published by Wiley in Pediatric Dermatology
- Vol. 39 (2) , 288-290
Open AccessA rare presentation of herpes simplex virus encephalitis occurring in a pediatric patient on dupilumab for atopic dermatitis
A 4‐year‐old female with a history of atopic dermatitis developed herpes simplex virus (HSV) encephalitis while being treated with dupilumab and concomitant topical steroids. There was no prior history of HSV infections or immunodeficiency. To our knowledge, this is the first case of HSV encephalitis in a patient receiving dupilumab.
- 8 November 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (6) , 1581-1582
Severe hypertriglyceridemia following sirolimus use in an infant
Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off‐label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.
- 8 November 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (6) , 1581-1582
Severe hypertriglyceridemia following sirolimus use in an infant
Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off‐label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.
- Open Access
- 22 September 2021
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (11) , 1328-1334
Mapping of Segmental and Partial Segmental Infantile Hemangiomas of the Face and Scalp
The distinction between localized infantile hemangiomas (IHs) and segmental IHs has helped in both risk stratification and understanding of hemangioma pathogenesis. Localized IHs are spatially confined, often surrounding a central focal point, whereas segmental IHs involve an anatomic territory, with many corresponding to known embryologic developmental units. Some IHs have been more difficult to classify and have been referred to as indeterminate.1,2 Indeterminate hemangiomas lack the round or ovoid shape of many localized hemangiomas yet are smaller in size than classic segmental lesions and fail to encompass the majority of a segmental unit as defined by IH segment maps.1
- 22 September 2021
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (11) , 1328-1334
Open AccessMapping of Segmental and Partial Segmental Infantile Hemangiomas of the Face and Scalp
The distinction between localized infantile hemangiomas (IHs) and segmental IHs has helped in both risk stratification and understanding of hemangioma pathogenesis. Localized IHs are spatially confined, often surrounding a central focal point, whereas segmental IHs involve an anatomic territory, with many corresponding to known embryologic developmental units. Some IHs have been more difficult to classify and have been referred to as indeterminate.1,2 Indeterminate hemangiomas lack the round or ovoid shape of many localized hemangiomas yet are smaller in size than classic segmental lesions and fail to encompass the majority of a segmental unit as defined by IH segment maps.1
- Open Access
- 16 May 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (3) , 412-418
Management of infantile hemangiomas during the COVID pandemic
The COVID‐19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long‐term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMA‐approved monitoring guidelines, clinical practice guidelines, and relevant, up‐to‐date publications regarding initiation and monitoring of beta‐blocker therapy were used to inform the recommendations. Clinical decision‐making guidelines about when telehealth is an appropriate alternative to in‐office visits, including medication initiation, dosage changes, and ongoing evaluation, are included. The importance of communication with caregivers in the context of telemedicine is discussed, and online resources for both hemangioma education and propranolol therapy are provided.
- 16 May 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (3) , 412-418
Open AccessManagement of infantile hemangiomas during the COVID pandemic
The COVID‐19 pandemic has caused significant shifts in patient care including a steep decline in ambulatory visits and a marked increase in the use of telemedicine. Infantile hemangiomas (IH) can require urgent evaluation and risk stratification to determine which infants need treatment and which can be managed with continued observation. For those requiring treatment, prompt initiation decreases morbidity and improves long‐term outcomes. The Hemangioma Investigator Group has created consensus recommendations for management of IH via telemedicine. FDA/EMA‐approved monitoring guidelines, clinical practice guidelines, and relevant, up‐to‐date publications regarding initiation and monitoring of beta‐blocker therapy were used to inform the recommendations. Clinical decision‐making guidelines about when telehealth is an appropriate alternative to in‐office visits, including medication initiation, dosage changes, and ongoing evaluation, are included. The importance of communication with caregivers in the context of telemedicine is discussed, and online resources for both hemangioma education and propranolol therapy are provided.
- 1 May 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (3) , 524-526
Segmental infantile hemangioma and concomitant hypertension in three African American neonates
We present three African American infants with segmental, ulcerated infantile hemangiomas and concomitant, persistent hypertension. When treated with beta-blocker therapy, the hemangiomas decreased in size and the ulcerations resolved, but there was no impact on the elevated blood pressure in one of our patients. We failed to identify any associations between infantile hemangioma and hypertension in the literature.
- 1 May 2020
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (3) , 524-526
Segmental infantile hemangioma and concomitant hypertension in three African American neonates
We present three African American infants with segmental, ulcerated infantile hemangiomas and concomitant, persistent hypertension. When treated with beta-blocker therapy, the hemangiomas decreased in size and the ulcerations resolved, but there was no impact on the elevated blood pressure in one of our patients. We failed to identify any associations between infantile hemangioma and hypertension in the literature.
- 20 October 2019
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (1) , 165-170
Bathing suit ichthyosis: Two Burmese siblings and a review of the literature
Bathing suit ichthyosis (BSI) is a subtype of autosomal recessive congenital ichthyosis (ARCI) characterized by the development of large platelike scales mainly limited to the trunk. It is caused by temperature sensitive variants in transglutaminase 1, encoded by the gene TGM1. We describe a rare case of intrafamilial variation in phenotypic expressivity in two Burmese siblings with BSI that demonstrates the heterogeneity of the disorder within the same family and even in the same individual across time. We also present a concise review of the genotypic spectrum of BSI from 54 cases reported in the literature as evidence that both environmental and additional genetic factors can significantly alter the clinical phenotype.
- 20 October 2019
- Published by Wiley in Pediatric Dermatology
- Vol. 37 (1) , 165-170
Bathing suit ichthyosis: Two Burmese siblings and a review of the literature
Bathing suit ichthyosis (BSI) is a subtype of autosomal recessive congenital ichthyosis (ARCI) characterized by the development of large platelike scales mainly limited to the trunk. It is caused by temperature sensitive variants in transglutaminase 1, encoded by the gene TGM1. We describe a rare case of intrafamilial variation in phenotypic expressivity in two Burmese siblings with BSI that demonstrates the heterogeneity of the disorder within the same family and even in the same individual across time. We also present a concise review of the genotypic spectrum of BSI from 54 cases reported in the literature as evidence that both environmental and additional genetic factors can significantly alter the clinical phenotype.
- 4 December 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (1) , 132-138
Epidermolysis bullosa simplex–generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype‐phenotype correlation and in silico modeling analysis
Background/Objectives: Epidermolysis bullosa is a group of diseases caused by mutations in skin structural proteins. Availability of genetic sequencing makes identification of causative mutations easier, and genotype‐phenotype description and correlation are important. We describe six patients with a keratin 5 mutation resulting in a glutamic acid to lysine substitution at position 477 (p.Glu477Lys) who have a distinctive, severe and sometimes fatal phenotype. We also perform in silico modeling to show protein structural changes resulting in instability.Methods: In this case series, we collected clinical data from six patients with this mutation identified from their national or local epidermolysis bullosa databases. We performed in silico modeling of the keratin 5‐keratin 14 coil 2B complex using CCBuilder and rendered with Pymol (Schrodinger, LLC, New York, NY).Results: Features include aplasia cutis congenita, generalized blistering, palmoplantar keratoderma, onychodystrophy, airway and developmental abnormalities, and a distinctive reticulated skin pattern. Our in silico model of the keratin 5 p.Glu477Lys mutation predicts conformational change and modification of the surface charge of the keratin heterodimer, severely impairing filament stability.Conclusions: Early recognition of the features of this genotype will improve care. In silico analysis of mutated keratin structures provides useful insights into structural instability.
- 4 December 2018
- Published by Wiley in Pediatric Dermatology
- Vol. 36 (1) , 132-138
Epidermolysis bullosa simplex–generalized severe type due to keratin 5 p.Glu477Lys mutation: Genotype‐phenotype correlation and in silico modeling analysis
Background/Objectives: Epidermolysis bullosa is a group of diseases caused by mutations in skin structural proteins. Availability of genetic sequencing makes identification of causative mutations easier, and genotype‐phenotype description and correlation are important. We describe six patients with a keratin 5 mutation resulting in a glutamic acid to lysine substitution at position 477 (p.Glu477Lys) who have a distinctive, severe and sometimes fatal phenotype. We also perform in silico modeling to show protein structural changes resulting in instability.Methods: In this case series, we collected clinical data from six patients with this mutation identified from their national or local epidermolysis bullosa databases. We performed in silico modeling of the keratin 5‐keratin 14 coil 2B complex using CCBuilder and rendered with Pymol (Schrodinger, LLC, New York, NY).Results: Features include aplasia cutis congenita, generalized blistering, palmoplantar keratoderma, onychodystrophy, airway and developmental abnormalities, and a distinctive reticulated skin pattern. Our in silico model of the keratin 5 p.Glu477Lys mutation predicts conformational change and modification of the surface charge of the keratin heterodimer, severely impairing filament stability.Conclusions: Early recognition of the features of this genotype will improve care. In silico analysis of mutated keratin structures provides useful insights into structural instability.